Chronicle Journal: Finance

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

(NQ: )

N/A UNCHANGED
Last Price Updated: Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close -
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Lilly Completes Acquisition of CoLucid Pharmaceuticals
Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of CoLucid Pharmaceuticals, Inc. (NASD:CLCD). The tender offer for all outstanding shares of common stock... 
From PR Newswire
Former CoLucid CEO Thomas P. Mathers joins Pappas Capital as Partner
Pappas Capital announced today that Thomas P. "Tom" Mathers has joined the firm as a partner. Mathers previously served as CEO of CoLucid Pharmaceuticals (NASDAQ: CLCD), a Pappas Capital portfolio... 
From PR Newswire

Performance

More News

Read More
Post Earnings Coverage as Eli Lilly's Q4 Revenue Beat Market Estimates
From ACCESSWIRE
Bragar Eagel & Squire, P.C. Is Investigating the Board of Directors of CoLucid Pharmaceuticals, Inc. (CLCD) on Behalf of Stockholders and Encourages Investors to Contact the Firm
From Business Wire News Releases
Hopeful of Reduced Regulation, Biotech Stocks Stay the Course with Advanced Drug Developments
From PR Newswire
FDA Watch: February's Notable PDUFA Dates
Tags Benzinga LXRX Health Care
From Benzinga
IPO Preview: Biohaven Pharmaceuticals
Tags Healthcare Stocks / Equities
From Blogs - TalkMarkets
Lawsuit Filed for Investors in Shares of CoLucid Pharmaceuticals Inc (NASDAQ:CLCD) in Effort to Halt the Takeover by Eli Lilly and Company
From SBWire - Latest Press Releases
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders -- CLCD
From PR Newswire
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of CoLucid Pharmaceuticals, Inc. to Eli Lilly & Co. for $46.50 Per Share is Fair to Shareholders
From Business Wire News Releases
NASDAQ:CLCD Investor Notice: Investigation of Takeover of CoLucid Pharmaceuticals Inc
From SBWire - Latest Press Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Chronicle Journal, Thunder Bay, ON. Powered by BLOX Content Management System from TownNews.com. [Terms of Use | Privacy Policy]